SAN ANTONIO (EGMN) - The routine use of adjuvant trastuzumab to prevent recurrent HER2-positive breast cancer would result in a societal savings of roughly $188 million annually in the United States, according to a health economic analysis. The analysis factored in direct medical costs resulting from recurrent disease, the related time lost from work, and the need for early retirement.However, the net societal savings accrued by preventing recurrences of HER2 (human epidermal growth factor receptor...